MXCT (MaxCyte) Total Long-Term Assets: $71.54 Mil (As of Mar. 2026)


MXCT MaxCyte Inc MXCT
64 GF Score
Price $1.33
GF Value $2.57
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Total Long-Term Assets?

MaxCyte MXCT +3.91% 64 Total Long-Term Assets is $71.54 Mil as of Mar. 2026. GuruFocus rates MXCT with a GF Score™ of 64/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. MaxCyte's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $71.54 Mil.

MaxCyte Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for MaxCyte's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MaxCyte Total Long-Term Assets Chart

MaxCyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.69 34.39 78.08 67.79 84.14

MaxCyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.21 76.53 88.83 84.14 71.54
MXCT
64GF Score
MaxCyte Inc MXCT
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MaxCyte Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $71.54 Mil mean?
MaxCyte (MXCT) has a Total Long-Term Assets of $71.54 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on MaxCyte and its competitors.
Is MaxCyte's Total Long-Term Assets too high?
MaxCyte's current Total Long-Term Assets is $71.54 Mil. Overall, MaxCyte has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Total Long-Term Assets compare to RCEL and HYPR?
MaxCyte's Total Long-Term Assets of $71.54 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on MaxCyte and its competitors. MaxCyte's current Total Long-Term Assets is $71.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.33 — trading 48.4% below its estimated fair value. The current Total Long-Term Assets is $71.54 Mil. MaxCyte's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For MaxCyte (MXCT), the current Total Long-Term Assets is $71.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.33 is trading 48.4% below its estimated GF Value™ of $2.57. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Total Long-Term Assets: $71.54 Mil
  • GF Value™: $2.57 vs. price of $1.33 (48.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
64GF Score

Get the complete analysis for MXCT

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price
$2.57
GF Value